(Q47362322)

14 January 2018

title

Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation (English)

1 reference

14 January 2018

author

Mir-Farzin Mashreghi

8

1 reference

14 January 2018

author name string

Mareen Matz

1

1 reference

14 January 2018

Martin Lehnert

2

1 reference

14 January 2018

Christine Lorkowski

3

1 reference

14 January 2018

Katharina Fabritius

4

1 reference

14 January 2018

Nadine Unterwalder

5

1 reference

14 January 2018

Salim Doueiri

6

1 reference

14 January 2018

Ulrike A Weber

7

1 reference

14 January 2018

Hans-H Neumayer

9

1 reference

14 January 2018

Klemens Budde

10

1 reference

14 January 2018

publication date

21 July 2012

1 reference

14 January 2018

published in

Transplant International

1 reference

14 January 2018

volume

25

1 reference

14 January 2018

issue

10

1 reference

14 January 2018

page(s)

1106-1116

1 reference

14 January 2018

Revisiting traditional risk factors for rejection and graft loss after kidney transplantation

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Deciphering antibody-mediated rejection: new insights into mechanisms and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

The (re)emergence of B cells in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Prevention and treatment of alloantibody-mediated kidney transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

B-cell immunotherapeutics: emerging roles in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Antibody-mediated rejection in kidney transplantation: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Proteasome inhibitor therapy for antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Toll-like receptor stimulation as a third signal required for activation of human naive B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Humoral theory of transplantation: mechanism, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Humoral theory of transplantation: further evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

De novo anti-HLA antibody responses after renal transplantation: detection and clinical impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Humoral immunity in renal transplantation: clinical significance and therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Effects of the new immunosuppressive agent AEB071 on human immune cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Differential regulation of mRNAs encoding protein kinase C isoenzymes in activated human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Protein kinase C family functions in B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

B cell receptor directs the activation of NFAT and NF-kappaB via distinct molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Induction of NF-AT in normal B lymphocytes by anti-immunoglobulin or CD40 ligand in conjunction with IL-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Interleukin-4 biases differentiation of B cells from Trypanosoma cruzi-infected mice and restrains their fratricide: role of Fas ligand down-regulation and MHC class II-transactivator up-regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

New treatments for acute humoral rejection of kidney allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Mycophenolic acid is a potent inhibitor of the expression of tumour necrosis factor‐ and tumour necrosis factor‐receptor superfamily costimulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2012.01537.X

10.1111/J.1432-2277.2012.01537.X

21 January 2018

Identifiers

DOI

1 reference

14 January 2018

1 reference

14 January 2018